Today GenVec, Inc. (Nasdaq:GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the Merriman Curhan Ford 5th Annual Investor Summit on Monday, September 15, 2008 at 10:45 a.m. PDT at the Mark Hopkins Intercontinental Hotel in San Francisco.
A webcast of Dr. Fischer's presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data." The replay will be available 24 hours after the live presentation and will be accessible for 30 days.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product candidate, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer and is being evaluated in additional clinical trials in other tumor types. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including foot-and-mouth disease, malaria, HIV, respiratory syncytial virus (RSV), HSV-2, and influenza. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
About Merriman Curhan Ford
Merriman Curhan Ford (Nasdaq:MERR) is a financial services firm focused on fast-growing companies and the institutions who invest in them. The company offers high-quality investment banking, equity research, institutional services, primary market research, asset management and corporate & venture services, and specializes in four growth industry sectors: CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. For more information, please go to www.mcfco.com.
